phenylalanine has been researched along with naltrexone in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 8 (44.44) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhargava, HN | 1 |
| Legator, MS; Truong, L; Ward, JB | 1 |
| Fournié-Zaluski, MC; Noble, F; Roques, BP; Turcaud, S | 1 |
| Blommaert, A; Fournié-Zaluski, MC; Noble, F; Roques, BP | 1 |
| Corringer, PJ; Dauge, V; Roques, BP | 1 |
| Noble, F; Roques, BP; Smadja, C | 1 |
| Krylatov, AV; Lishmanov, IuB; Maslov, LN; Uskina, EV | 1 |
| Fournié-Zaluski, MC; Fuentes, JA; Hernando, F; Roques, BP; Ruiz-Gayo, M | 1 |
| Gilbert-Rahola, J; Maldonado, R; Micó, JA; Roques, BP; Smadja, C; Tejedor-Real, P | 1 |
| Besson, JM; Catheline, G; Fournié-Zaluski, MC; Honoré, P; Le Guen, S; Roques, BP | 1 |
| Boucher, M; Coudoré-Civiale, MA; Eschalier, A; Fournié-Zaluski, MC; Méen, M; Roques, BP | 1 |
| Blum, K; Braverman, ER; Chen, TJ; Hopper, D; Payte, JT; Schoolfield, J; Stanford, M | 1 |
| Guen, SL; Kieffer, BL; Nieto, MM; Noble, F; Roques, BP | 1 |
| Folk, JE; Jutkiewicz, EM; Mosberg, HI; Rice, KC; Sobczyk-Kojiro, K; Torregrossa, MM; Watson, SJ; Woods, JH | 1 |
| Benturquia, N; Bilkei-Gorzo, A; Noble, F; Roques, BP; Zimmer, A | 1 |
| Bouvier, M; Kobayashi, H; Lackman, JJ; Leskelä, TT; Petäjä-Repo, UE; Vierimaa, MM | 1 |
| Akbarali, HI; Dewey, WL; Komla, E; Obeng, S; Selley, DE; Stevens, DL; Wang, H; Zhang, Y; Zheng, Y | 1 |
| Corsetti, M; Pannemans, J | 1 |
1 review(s) available for phenylalanine and naltrexone
| Article | Year |
|---|---|
Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?
Topics: Analgesics, Opioid; Animals; Antidiarrheals; Constipation; Defecation; Diarrhea; Gastrointestinal Motility; Gastrointestinal Tract; Humans; Imidazoles; Inflammatory Bowel Diseases; Laxatives; Morphinans; Naltrexone; Narcotic Antagonists; Phenylalanine; Polyethylene Glycols; Quaternary Ammonium Compounds; Receptors, Opioid, mu; Signal Transduction | 2018 |
1 trial(s) available for phenylalanine and naltrexone
| Article | Year |
|---|---|
Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy.
Topics: Adult; Aged; Amino Acids; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neprilysin; Opioid-Related Disorders; Patient Compliance; Phenylalanine; Pilot Projects; Secondary Prevention; Texas; Treatment Outcome | 2004 |
16 other study(ies) available for phenylalanine and naltrexone
| Article | Year |
|---|---|
Studies of the possible role of brain endorphins in pentobarbital anesthesia and toxicity in mice.
Topics: Animals; Brain; Endorphins; Enkephalins; Leucine; Male; Mice; Morphine; Naloxone; Naltrexone; Pentobarbital; Phenylalanine | 1979 |
Detection of alkylating agents by the analysis of amino acid residues in hemoglobin and urine. 1. The in vivo and in vitro effects of ethyl methanesulfonate, methyl methanesulfonate, hycanthone methanesulfonate, and naltrexone.
Topics: Alkylating Agents; Amino Acid Sequence; Amino Acids; Animals; Ethyl Methanesulfonate; Hemoglobins; Histidine; Humans; Hycanthone; Male; Methyl Methanesulfonate; Naltrexone; Phenylalanine; Proline; Rats | 1978 |
Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine.
Topics: Analgesics; Animals; Disulfides; Dose-Response Relationship, Drug; Drug Tolerance; Indoles; Male; Mice; Morphinans; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Phenylalanine; Prodrugs; Reaction Time | 1992 |
A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
Topics: Analgesics; Animals; Disulfides; Enkephalins; Formaldehyde; Indoles; Male; Meglumine; Mice; Morphine; Naloxone; Naltrexone; Pain Measurement; Phenylalanine; Receptors, Cholecystokinin; Receptors, Opioid, delta; Receptors, Opioid, mu | 1995 |
CCKA, but not CCKB, agonists suppress the hyperlocomotion induced by endogenous enkephalins, protected from enzymatic degradation by systemic RB 101.
Topics: Amino Acid Sequence; Animals; Benzodiazepinones; Cholecystokinin; Devazepide; Disulfides; Enkephalins; Enzyme Inhibitors; Male; Mice; Molecular Sequence Data; Motor Activity; Naltrexone; Narcotic Antagonists; Peptide Fragments; Phenylalanine; Receptors, Cholecystokinin | 1995 |
Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists.
Topics: Amino Acid Sequence; Analgesia; Animals; Benzodiazepinones; Cholecystokinin; Devazepide; Disulfides; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Male; Mice; Molecular Sequence Data; Naloxone; Naltrexone; Oligopeptides; Peptide Fragments; Phenylalanine; Receptors, Opioid, delta; Receptors, Opioid, mu; Sincalide | 1994 |
[Opiatergic mechanisms of antiarrhythmic effect of adaptation].
Topics: Adaptation, Physiological; Animals; Arrhythmias, Cardiac; Calcium Chloride; Disulfides; Endorphins; Enzyme Inhibitors; Epinephrine; Male; Naltrexone; Narcotic Antagonists; Neprilysin; Phenylalanine; Rats; Rats, Wistar; Receptors, Opioid | 1996 |
Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system.
Topics: Animals; Antidepressive Agents; Benzodiazepinones; Devazepide; Disulfides; Endorphins; Male; Mice; Naloxone; Naltrexone; Phenylalanine; Phenylurea Compounds; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Sincalide | 1996 |
Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model.
Topics: Analgesics; Animals; Behavior, Animal; Disulfides; Drug Interactions; Enkephalins; Helplessness, Learned; Male; Naltrexone; Narcotic Antagonists; Oligopeptides; Phenylalanine; Rats; Rats, Wistar; Receptors, Opioid, delta | 1998 |
The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by beta-funaltrexamine, a selective mu-opioid receptor antagonist.
Topics: Animals; Carrageenan; Disulfides; Enzyme Inhibitors; Male; Naltrexone; Narcotic Antagonists; Neprilysin; Phenylalanine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Spinal Cord | 1999 |
Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
Topics: Aminopeptidases; Animals; Diabetes Mellitus, Experimental; Disulfides; Drug Synergism; Indoles; Male; Meglumine; Naloxone; Naltrexone; Neprilysin; Pain; Pain Measurement; Phenylalanine; Pressure; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Time Factors; Vocalization, Animal; Weight Loss | 2001 |
Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Disulfides; Dose-Response Relationship, Drug; Drug Interactions; Emotions; Enkephalins; Enzyme Inhibitors; Exploratory Behavior; Freezing Reaction, Cataleptic; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Pain Measurement; Phenylalanine; Reaction Time; Receptors, Opioid, delta; Receptors, Opioid, mu; Swimming; Time Factors | 2005 |
Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Brain-Derived Neurotrophic Factor; Disulfides; Dose-Response Relationship, Drug; Electroencephalography; Enzyme Inhibitors; Frontal Lobe; Hippocampus; Injections, Intravenous; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Neprilysin; Phenylalanine; Piperazines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Swimming | 2006 |
Use of preproenkephalin knockout mice and selective inhibitors of enkephalinases to investigate the role of enkephalins in various behaviours.
Topics: Analysis of Variance; Animals; Behavior, Animal; CD13 Antigens; Disulfides; Dose-Response Relationship, Drug; Enkephalins; Enzyme Inhibitors; Injections, Intravenous; Mice; Mice, Inbred DBA; Mice, Knockout; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Neprilysin; Phenylalanine; Protein Precursors; Swimming | 2008 |
Cys-27 variant of human δ-opioid receptor modulates maturation and cell surface delivery of Phe-27 variant via heteromerization.
Topics: Cell Line, Tumor; Endoplasmic Reticulum; HEK293 Cells; Humans; Naltrexone; Narcotic Antagonists; Phenylalanine; Protein Multimerization; Protein Precursors; Protein Transport; Proteolysis; Receptors, Opioid, delta | 2012 |
Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.
Topics: Analgesics, Opioid; Animals; CHO Cells; Constipation; Cricetulus; Diarrhea; Drug Partial Agonism; Gastrointestinal Agents; Gastrointestinal Transit; Imidazoles; Methylation; Mice; Molecular Docking Simulation; Morphine; Naltrexone; Narcotic Antagonists; Nociception; Phenylalanine; Quaternary Ammonium Compounds; Radioligand Assay; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2018 |